MA56222A - Polypeptides ciblant une fusion du vih - Google Patents

Polypeptides ciblant une fusion du vih

Info

Publication number
MA56222A
MA56222A MA056222A MA56222A MA56222A MA 56222 A MA56222 A MA 56222A MA 056222 A MA056222 A MA 056222A MA 56222 A MA56222 A MA 56222A MA 56222 A MA56222 A MA 56222A
Authority
MA
Morocco
Prior art keywords
hiv fusion
targeting polypeptides
fusion targeting
polypeptides
hiv
Prior art date
Application number
MA056222A
Other languages
English (en)
Inventor
Jonathan Davis
Mark R Krystal
David L Wensel
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA56222A publication Critical patent/MA56222A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
MA056222A 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih MA56222A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US201562257474P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
MA56222A true MA56222A (fr) 2022-04-20

Family

ID=55809237

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056222A MA56222A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih
MA041943A MA41943A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA041943A MA41943A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih

Country Status (25)

Country Link
US (2) US10407490B2 (fr)
EP (2) EP3985020A1 (fr)
JP (3) JP6894846B2 (fr)
KR (1) KR20170138558A (fr)
CN (1) CN107922474A (fr)
AU (2) AU2016252008B2 (fr)
BR (1) BR112017022790A2 (fr)
CA (1) CA2983276A1 (fr)
CL (1) CL2017002687A1 (fr)
CO (1) CO2017011583A2 (fr)
CR (1) CR20170482A (fr)
DO (1) DOP2017000246A (fr)
EA (1) EA035332B1 (fr)
ES (1) ES2884267T3 (fr)
HK (1) HK1243432A1 (fr)
IL (1) IL255122A0 (fr)
MA (2) MA56222A (fr)
MX (1) MX2017013687A (fr)
PE (1) PE20180162A1 (fr)
PH (1) PH12017501914A1 (fr)
PT (1) PT3286212T (fr)
SG (1) SG11201708441RA (fr)
TW (1) TW201643185A (fr)
UY (1) UY36650A (fr)
WO (1) WO2016171980A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑***和其靶向载运***
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (fr) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions et procédés pour le traitement du virus de l'immunodéficience humaine
WO2023030312A1 (fr) * 2021-08-30 2023-03-09 康霖生物科技（杭州）有限公司 Construction de séquence génique pour la thérapie génique contre l'infection par le vih

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU7786701A (en) 2000-07-11 2002-01-21 Res Corp Technologies Inc Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101152574A (zh) * 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
CA2554089C (fr) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
JP2011507543A (ja) 2007-12-27 2011-03-10 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
CA2723277A1 (fr) 2008-05-02 2009-11-05 Novartis Ag Molecules de liaison a base de fibronectine ameliorees et leurs utilisations
CA2741834C (fr) 2008-10-31 2022-04-05 Centocor Ortho Biotech Inc. Compositions d'echafaudage a base de domaines de la fibronectine de type iii, procedes et utilisations
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
CN103068843B (zh) * 2010-04-13 2015-09-09 百时美施贵宝公司 结合pcsk9的基于纤连蛋白的支架域蛋白质
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
MX2012012736A (es) * 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
WO2012088006A1 (fr) 2010-12-22 2012-06-28 Bristol-Myers Squibb Company Protéines à domaine échafaudage à base de fibronectine qui se lient à l'il-23
US9880151B2 (en) 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP2761066B1 (fr) 2011-09-27 2018-12-05 Janssen Biotech, Inc. Echafaudages protéiques à base de répétition de fibronectine type iii avec de nouvelles surfaces de liaison
WO2014120891A2 (fr) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine
EP2968587A2 (fr) * 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
US20180111980A1 (en) 2018-04-26
IL255122A0 (en) 2017-12-31
KR20170138558A (ko) 2017-12-15
WO2016171980A1 (fr) 2016-10-27
BR112017022790A2 (pt) 2018-07-17
PT3286212T (pt) 2021-08-24
JP2021035951A (ja) 2021-03-04
CN107922474A (zh) 2018-04-17
CL2017002687A1 (es) 2018-04-20
HK1243432A1 (zh) 2018-07-13
EA035332B1 (ru) 2020-05-28
JP2018516247A (ja) 2018-06-21
MX2017013687A (es) 2018-07-06
EP3286212B1 (fr) 2021-06-02
DOP2017000246A (es) 2018-01-31
TW201643185A (zh) 2016-12-16
EP3286212A1 (fr) 2018-02-28
PE20180162A1 (es) 2018-01-18
PH12017501914A1 (en) 2018-03-05
AU2016252008A1 (en) 2017-11-09
SG11201708441RA (en) 2017-11-29
UY36650A (es) 2016-11-30
JP7465378B2 (ja) 2024-04-10
MA41943A (fr) 2018-02-28
US20190359688A1 (en) 2019-11-28
CA2983276A1 (fr) 2016-10-27
JP6894846B2 (ja) 2021-06-30
EA201792269A1 (ru) 2018-04-30
CO2017011583A2 (es) 2018-04-19
AU2019226255A1 (en) 2019-09-26
ES2884267T3 (es) 2021-12-10
AU2016252008B2 (en) 2019-06-13
JP2023055875A (ja) 2023-04-18
CR20170482A (es) 2018-03-07
US11155602B2 (en) 2021-10-26
EP3985020A1 (fr) 2022-04-20
US10407490B2 (en) 2019-09-10

Similar Documents

Publication Publication Date Title
DK3292141T3 (da) Fusionsproteiner
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3268047T3 (da) Amatoxin/antistof-konjugater
DK3197453T3 (da) Kimært protein
DK4089113T3 (da) Polypeptider
DK3242884T3 (da) Kationiske neurotoksiner
DK3365563T3 (da) Forbindelseskomponent
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3362444T3 (da) Forbindelser
MA56222A (fr) Polypeptides ciblant une fusion du vih
FI20155191A (fi) Nivel
DK3113795T3 (da) Rekombinante virale isfahan-vektorer
DE102016001845A8 (de) Mangan-arme Schweißelektroden
DK3331885T3 (da) Forbindelser
CR20180079A (es) Moléculas de fusión
BR112016029235A2 (pt) Polipeptídeos de fusão relacionados com ômega- hidroxilase com propriedades aprimoradas
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
FI20155282A (fi) Kolmiakselinen gyroskooppi
FI20156045A (fi) Kationinen pintaliima-aine
DE112017000801A5 (de) Steglose Brille
ITUA20162867A1 (it) Interruttore differenziale
DK3302527T3 (da) Manipuleret CCL20-låst-dimerpolypeptid
FI20155255A (fi) Poltin
DE112016001702A5 (de) Gelenkanordnung
ES2775740T8 (es) Péptidos